Approval · Notice of Compliance 38273 · 2026
CLOPIDOGREL: Notice of Compliance 38273
Issued September 10, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38273
- Date
- September 10, 2026
- Company
- Sanis Health Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement between two manufacturers
- Canadian reference product
- PLAVIX (Sanofi-Aventis Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CLOPIDOGREL | 02400553 | Marketed |
| CLOPIDOGREL | 02571366 | Approved |
Medicinal ingredients
- CLOPIDOGREL BISULFATE 75 MG per TAB
- CLOPIDOGREL BISULFATE 300 MG per TAB